NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
25 hedge funds and large institutions have $5.07M invested in NKGen Biotech, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
312% more capital invested
Capital invested by funds: $1.23M → $5.07M (+$3.84M)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
32% more funds holding
Funds holding: 19 → 25 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pathstone Holdings
Englewood,
New Jersey
|
+$1.14M |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$769K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$109K |
| 4 |
KC
Kepos Capital
New York
|
+$93.8K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$35.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$278K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$36.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.66K |
| 4 |
TCM
Towneley Capital Management
Laguna Hills,
California
|
-$3.78K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$36.1K | -95,438 | Closed |
|
|
HF
27
HRT Financial
New York
| – | -$3K | -10,318 | Closed |
|
|
TCM
28
Towneley Capital Management
Laguna Hills,
California
| – | -$3.78K | -10,000 | Closed |
|
NKGN Hedge Fund Activity: Q4 2024 in Review
25 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q4 2024, worth a combined $5.07M — up 312% from $1.23M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NKGN positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Pathstone Holdings, opening a new position worth an estimated $1.14M. The largest seller was Polar Asset Management Partners, cutting an estimated $278K.
- 25 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q4 2024, up from 19 in Q3 2024.
- Funds reported $5.07M of NKGen Biotech, Inc. Common Stock stock for Q4 2024, up 312% quarter-over-quarter.
- 9 funds opened new NKGen Biotech, Inc. Common Stock positions in Q4 2024 and 3 closed out, a net change of +6 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q4 2024 was Pathstone Holdings, an estimated $1.14M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q4 2024 was Polar Asset Management Partners, an estimated $278K sold.
Based on aggregated 13F filings for Q4 2024.